SCHEMBL2023282

SCHEMBL2023282

COc1ccc(Nc2ncnc3[nH]cc(C(=O)c4cccc5ccccc45)c23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TTBK1 Q5TCY1 2/20 0.47
TTBK2 Q6IQ55 2/20 0.47
NPC1 O15118 2/20 0.47
HTT P42858 2/20 0.47
RAB9A P51151 2/20 0.47
BTK Q06187 9/20 0.47
GAA P10253 1/20 0.46
BRAF P15056 1/20 0.44
TNNI3K Q59H18 1/20 0.44
DYRK1A Q13627 1/20 0.44
ALDH1A1 P00352 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PDPK1 O15530 1/20 0.43
CDC7 O00311 1/20 0.43
ROCK2 O75116 1/20 0.43
MAP4K4 O95819 1/20 0.43
PIM1 P11309 1/20 0.43
PRKACA P17612 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2021226 0.84 ERBB2 (0.52) BTKCDC7ROCK2MAP4K4PIM1
SCHEMBL2022444 0.83 BTK (0.51) HTTBTKBRAFTNNI3K
SCHEMBL2020584 0.82 ABCG2 (0.55) BTK
SCHEMBL2021419 0.81 EGFR (0.54) BRAFTNNI3K
SCHEMBL2022472 0.81 EGFR (0.48) HTTBTKBRAFTNNI3KDYRK1A
SCHEMBL2023296 0.81 BRAF (0.46) HTTBTKBRAFTNNI3KNPSR1
SCHEMBL2021310 0.81 BRAF (0.45) BTKBRAFTNNI3K
SCHEMBL2020574 0.80 BTK (0.48) BTKBRAFTNNI3K
SCHEMBL2016580 0.80 BTK (0.49) TTBK1TTBK2NPC1BTKALDH1A1
SCHEMBL2019190 0.79 SYK (0.48) SMN1; SMN2NPC1RAB9ABTKBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
WO-2011082273-A2 SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds DPYD, TYMP, DHFR GCGR 3244/4885SMN1; SMN2 2070/4885TTBK1 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.